vs
CSW INDUSTRIALS, INC.（CSW）とPacira BioSciences, Inc.（PCRX）の財務データ比較。上の社名をクリックして会社を切り替えられます
CSW INDUSTRIALS, INC.の直近四半期売上が大きい（$233.0M vs $177.4M、Pacira BioSciences, Inc.の約1.3倍）。CSW INDUSTRIALS, INC.の純利益率が高く（4.4% vs 1.6%、差は2.8%）。CSW INDUSTRIALS, INC.の前年同期比売上増加率が高い（20.3% vs 5.0%）。過去8四半期でCSW INDUSTRIALS, INC.の売上複合成長率が高い（5.1% vs -0.2%）
Pacira BioSciences社は非オピオイド系疼痛管理ソリューションの開発・商業化に特化した専門製薬企業で、主に米国の病院や外来手術センターなどの医療機関に術後鎮痛向け製品を提供し、一部海外市場への展開も進めています。
CSW vs PCRX — 直接比較
売上が大きい
CSW
1.3倍大きい
$177.4M
売上成長率が高い
CSW
+15.3%の差
5.0%
純利益率が高い
CSW
純利益率が2.8%高い
1.6%
2年売上CAGRが高い
CSW
2年複合成長率
-0.2%
損益計算書 — Q3 FY2026 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $233.0M | $177.4M |
| 純利益 | $10.3M | $2.9M |
| 粗利率 | 39.7% | — |
| 営業利益率 | 7.4% | 3.9% |
| 純利益率 | 4.4% | 1.6% |
| 売上前年比 | 20.3% | 5.0% |
| 純利益前年比 | -61.9% | — |
| EPS（希薄化後） | $0.62 | $0.07 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上CSWPCRX
| Q1 26 | — | $177.4M | ||
| Q4 25 | $233.0M | $196.9M | ||
| Q3 25 | $277.0M | $179.5M | ||
| Q2 25 | $263.6M | $181.1M | ||
| Q1 25 | $230.5M | $168.9M | ||
| Q4 24 | $193.6M | $187.3M | ||
| Q3 24 | $227.9M | $168.6M | ||
| Q2 24 | $226.2M | $178.0M |
純利益CSWPCRX
| Q1 26 | — | $2.9M | ||
| Q4 25 | $10.3M | — | ||
| Q3 25 | $40.7M | $5.4M | ||
| Q2 25 | $40.9M | $-4.8M | ||
| Q1 25 | $35.1M | $4.8M | ||
| Q4 24 | $26.9M | — | ||
| Q3 24 | $36.1M | $-143.5M | ||
| Q2 24 | $38.6M | $18.9M |
粗利率CSWPCRX
| Q1 26 | — | — | ||
| Q4 25 | 39.7% | 79.5% | ||
| Q3 25 | 43.0% | 80.9% | ||
| Q2 25 | 43.8% | 77.4% | ||
| Q1 25 | 44.2% | 79.7% | ||
| Q4 24 | 41.4% | 78.7% | ||
| Q3 24 | 45.6% | 76.9% | ||
| Q2 24 | 47.5% | 75.1% |
営業利益率CSWPCRX
| Q1 26 | — | 3.9% | ||
| Q4 25 | 7.4% | 1.2% | ||
| Q3 25 | 20.5% | 3.5% | ||
| Q2 25 | 20.8% | 4.7% | ||
| Q1 25 | 19.5% | 1.2% | ||
| Q4 24 | 15.3% | 13.2% | ||
| Q3 24 | 22.6% | -82.8% | ||
| Q2 24 | 24.3% | 15.9% |
純利益率CSWPCRX
| Q1 26 | — | 1.6% | ||
| Q4 25 | 4.4% | — | ||
| Q3 25 | 14.7% | 3.0% | ||
| Q2 25 | 15.5% | -2.7% | ||
| Q1 25 | 15.2% | 2.8% | ||
| Q4 24 | 13.9% | — | ||
| Q3 24 | 15.8% | -85.1% | ||
| Q2 24 | 17.1% | 10.6% |
EPS（希薄化後）CSWPCRX
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.62 | $0.05 | ||
| Q3 25 | $2.41 | $0.12 | ||
| Q2 25 | $2.43 | $-0.11 | ||
| Q1 25 | $2.05 | $0.10 | ||
| Q4 24 | $1.60 | $0.38 | ||
| Q3 24 | $2.26 | $-3.11 | ||
| Q2 24 | $2.47 | $0.39 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $40.2M | $144.3M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $1.1B | $653.9M |
| 総資産 | $2.3B | $1.2B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
現金・短期投資CSWPCRX
| Q1 26 | — | $144.3M | ||
| Q4 25 | $40.2M | $238.4M | ||
| Q3 25 | $31.5M | $246.3M | ||
| Q2 25 | $38.0M | $445.9M | ||
| Q1 25 | $225.8M | $493.6M | ||
| Q4 24 | $213.8M | $484.6M | ||
| Q3 24 | $273.2M | $453.8M | ||
| Q2 24 | $18.9M | $404.2M |
総負債CSWPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | $800.1M | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
株主資本CSWPCRX
| Q1 26 | — | $653.9M | ||
| Q4 25 | $1.1B | $693.1M | ||
| Q3 25 | $1.1B | $727.2M | ||
| Q2 25 | $1.1B | $757.8M | ||
| Q1 25 | $1.1B | $798.5M | ||
| Q4 24 | $1.0B | $778.3M | ||
| Q3 24 | $1.0B | $749.6M | ||
| Q2 24 | $650.2M | $879.3M |
総資産CSWPCRX
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.3B | $1.3B | ||
| Q3 25 | $1.5B | $1.3B | ||
| Q2 25 | $1.5B | $1.5B | ||
| Q1 25 | $1.4B | $1.6B | ||
| Q4 24 | $1.4B | $1.6B | ||
| Q3 24 | $1.4B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B |
負債/資本比率CSWPCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | 0.75× | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $28.9M | — |
| フリーキャッシュフロー営業CF - 設備投資 | $22.7M | — |
| FCFマージンFCF / 売上 | 9.8% | — |
| 設備投資強度設備投資 / 売上 | 2.6% | — |
| キャッシュ転換率営業CF / 純利益 | 2.81× | — |
| 直近12ヶ月FCF直近4四半期 | $162.0M | — |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローCSWPCRX
| Q1 26 | — | — | ||
| Q4 25 | $28.9M | $43.7M | ||
| Q3 25 | $61.8M | $60.8M | ||
| Q2 25 | $60.6M | $12.0M | ||
| Q1 25 | $27.3M | $35.5M | ||
| Q4 24 | $11.6M | $33.1M | ||
| Q3 24 | $66.8M | $53.9M | ||
| Q2 24 | $62.7M | $53.2M |
フリーキャッシュフローCSWPCRX
| Q1 26 | — | — | ||
| Q4 25 | $22.7M | $43.5M | ||
| Q3 25 | $58.7M | $57.0M | ||
| Q2 25 | $57.7M | $9.3M | ||
| Q1 25 | $22.8M | $26.9M | ||
| Q4 24 | $8.5M | $31.0M | ||
| Q3 24 | $61.3M | $49.8M | ||
| Q2 24 | $59.6M | $51.6M |
FCFマージンCSWPCRX
| Q1 26 | — | — | ||
| Q4 25 | 9.8% | 22.1% | ||
| Q3 25 | 21.2% | 31.7% | ||
| Q2 25 | 21.9% | 5.1% | ||
| Q1 25 | 9.9% | 15.9% | ||
| Q4 24 | 4.4% | 16.6% | ||
| Q3 24 | 26.9% | 29.6% | ||
| Q2 24 | 26.3% | 29.0% |
設備投資強度CSWPCRX
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | 0.1% | ||
| Q3 25 | 1.1% | 2.2% | ||
| Q2 25 | 1.1% | 1.5% | ||
| Q1 25 | 2.0% | 5.1% | ||
| Q4 24 | 1.6% | 1.1% | ||
| Q3 24 | 2.4% | 2.4% | ||
| Q2 24 | 1.4% | 0.9% |
キャッシュ転換率CSWPCRX
| Q1 26 | — | — | ||
| Q4 25 | 2.81× | — | ||
| Q3 25 | 1.52× | 11.20× | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 0.78× | 7.37× | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 1.85× | — | ||
| Q2 24 | 1.62× | 2.82× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
